The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study, yet was associated with brain bleeds in a significant number of patients.
The study was published in the New England Journal of Medicine on Tuesday, when Eisai also presented the data at the 2022 Clinical Trials on Alzheimer’s Disease conference in San Francisco. The data were heavily anticipated, since Eisai and Biogen claimed the drug, lecanemab, was a success by way of press release over two months ago.
More on this story from Boston Business Journal
Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters.
Copyright Boston Business Journal
